EpiCept Corp. (EPCT: OTCQX U.S.) | CEO of Immune

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
EpiCept Corp. (EPCT: OTCQX U.S.) | CEO of Immune Pharmaceuticals to Present at BioEquity Europe 2013

Contacts

 

Immune Pharmaceuticals:

15 Aba Even Avenue, 2nd Floor
Herzliya-Pituach, 46733, Israel

 

New York Office:

Anna Baran – Director of Corp. Development

Tel: (646) 937-1941

anna.baran@immunepharma.com

 

 

EpiCept Corporation:

777 Old Saw Mill River Road

Tarrytown, NY 10591

Robert W. Cook, CEO

Tel: (914) 606-3500

rcook@epicept.com

 

CEO of Immune Pharmaceuticals to Present at BioEquity Europe 2013
Update on Bertilimumab Development and EpiCept Merger Process

 

HERZLIYA-PITUACH, Israel and TARRYTOWN, N.Y. (May 22, 2013) – Immune Pharmaceuticals Ltd. (“Immune”), a privately held Israeli company, and EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced today that Daniel Teper, Chief Executive Officer of Immune, will be presenting at the BioEquity Europe 2013 conference at the Varumottagning Sheraton Hotel in Stockholm, Sweden on Thursday, May 23, at 1:30 PM local time in the St. Eriksalen Room.   Dr. Teper will provide an update on the Immune/EpiCept merger and present an overview of the companies' products bertilimumab, NanomAbs, and AmiKet.   The presentation will not be webcast, but the slide presentation will be available on both companies' websites."

About the Immune/EpiCept Merger

 

In November 2012, Immune and EpiCept announced that they had entered into a definitive merger agreement.  The transaction is currently anticipated to close during the third quarter of 2013 and is subject to satisfaction of certain customary closing conditions, including the approval of a majority of EpiCept shareholders.

 

Additional Information

 

In connection with the proposed merger transaction, EpiCept has filed a preliminary proxy statement with the U.S. Securities and Exchange Commission (SEC) and will file a definitive proxy statement with the SEC seeking appropriate stockholder approval.   STOCKHOLDERS OF EPICEPT AND OTHER INVESTORS ARE URGED TO READ THE PRELIMINARY PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS TO THE PRELIMINARY PROXY STATEMENT), WHICH IS AVAILABLE NOW, AND THE DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS TO THE DEFINITIVE PROXY STATEMENT) WHEN IT BECOMES AVAILABLE, REGARDING THE PROPOSED TRANSACTION BECAUSE IT CONTAINS AND WILL CONTAIN IMPORTANT INFORMATION.   EpiCept's stockholders can obtain a copy of the preliminary proxy statement, and will be able to obtain a copy of the definitive proxy statement when it becomes available, as well as other filings containing information about Immune and EpiCept, without charge, at the SEC's Internet site ( www.sec.gov ).   Copies of the preliminary proxy statement, and the definitive proxy statement when it becomes available, and any filings with the SEC that are incorporated by reference in the proxy statement can also be obtained, without charge, by directing a request to EpiCept Corporation, 777 Old Saw Mill River Rd, Tarrytown, NY 10591, Attention: Investor Relations, Telephone: (914) 606-3500.

Participants in the Solicitation

EpiCept and its directors and executive officers and Immune and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of EpiCept in connection with the proposed transaction.   Computer Share AB will assist EpiCept in soliciting proxies from Swedish stockholders.   Information regarding the direct and indirect interests of these directors and executive officers and Computer Share AB in EpiCept, Immune and the merger transaction is included in the preliminary proxy statement, and will be included in the definitive proxy statement when it becomes available, of EpiCept referred to above.   Additional information regarding the directors and executive officers of EpiCept is also included in EpiCept's Annual Report on Form 10-K for the fiscal year ended December 31, 2012, which was filed with the SEC on March 5, 2013.   This document is available free of charge at the SEC's web site ( www.sec.gov ) and from Investor Relations at EpiCept at the address described above.

 

This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the “Act”). The securities issued in exchange for all of the outstanding shares of Immune will not be and have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exception from registration requirements.

 

The merger agreement and any accompanying issuance of shares by Immune Pharmaceuticals are not, under any circumstances, to be construed as an advertisement or a public offering of securities in Israel. Any public offer or sale of securities in Israel may be made only in accordance with the Israeli Securities Act-1968 (which requires, inter alia, the filing of a prospectus in Israel or an exemption therefrom).

 

About Immune Pharmaceuticals Ltd.

 

Immune Pharmaceuticals Ltd. is an Israel and U.S.-based biopharmaceutical company, focused on the development of next generation antibody therapeutics addressing unmet medical needs in the treatment of inflammatory diseases and cancer. Immune licensed worldwide rights for systemic indications of bertilimumab from iCo Therapeutics (TSX: ICO) in June 2011, while iCo retained rights to all ophthalmic indications. iCo originally licensed the exclusive world-wide rights to bertilimumab in 2006 from Cambridge Antibody Technology Limited, now part of MedImmune, the global biologics research and development arm of AstraZeneca. Additionally, Immune has licensed from Yissum, the technology transfer company of the Hebrew University of Jerusalem, the injectable applications of the antibody nanoparticle conjugate technology (NanomAbs® ) developed by Professor Shimon Benita.  For more information, visit the Immune website at: www.immunepharmaceuticals.com

 

 

About EpiCept Corporation

 

EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of pain and cancer. The Company's pain portfolio includes AmiKet™, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies.   The Company's product Ceplene ® , when used concomitantly with low-dose IL-2, is intended as remission maintenance therapy in the treatment of AML for adult patients who are in their first complete remission.   The Company sold all of its rights to Ceplene ® in Europe and certain Pacific Rim countries and a portion of its remaining Ceplene ® inventory to Meda AB in June 2012.   Ceplene ® is licensed to MegaPharm Ltd. to market and sell in Israel and EpiCept has retained its rights to Ceplene ® in all other countries, including countries in North and South America.   The Company has other oncology drug candidates in clinical development that were discovered using in-house technology and have been shown to act as vascular disruption agents in a variety of solid tumors.

 

Forward-Looking Statements

 

This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements.   You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking.   Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that we may be unable to complete the proposed merger transaction, the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern, the risks associated with EpiCept’s ability to continue to meet its obligations under its existing debt agreements, the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet™ on attractive terms, a timely basis or at all, the risk that our product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials, the risk that we will not obtain approval to market any of our product candidates, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in EpiCept’s periodic reports, including reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in EpiCept’s filings which are available at www.sec.gov or at www.epicept.com . You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.

 

 

# # #

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 102

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 0

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading
SahajMobile's $25M Boost: Impact on Bangladesh Market

Updated Category News Views 0

Untapped Digital Frontier in Bangladesh There's an undeniable buzz around SahajMobile's recent $25 million credit facility, and it's one worth dissecting. This shot of capital, lined up with ALMA as part of SahajMobile’s Series A gamble, is setting the stage for a real shuffle in Bangladesh's digital landscape. Plugging into a Market Gap Ever since it hit the ground...

Continue Reading
Rock Tech Uncovers Major Lithium Discovery at Victory

Updated Category News Views 28

Rock Tech's Game-Changer at Victory Folks, we've got a shake-up in the lithium landscape over in Ontario, courtesy of Rock Tech Lithium Inc. They just unearthed something quite promising at their Victory Project: a spanking new spodumene-bearing pegmatite discovery. Now I know, if you're like me, you're thinking, 'What's the angle here?' Well, this isn't just another hole...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 116

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 215

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Peptide Tracker Refresh Unveils New Planning Features

Updated Category News Views 0

Peptide Tracker's Latest Updates: A Game Changer? I'll tell you what—if you're keeping tabs on your peptide intake like a seasoned gardener checks the soil, Peptide Tracker's fresh versions 3.2.0 and 3.3.0 might just be your new best mates. With the addition of washout scheduling and a robust six-month schedule preview, this isn't just another fancy tech update. It's...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 39

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 126

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 49

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Line-Up of Athletes for Future Games in Abu Dhabi

Updated Category News Views 298

Global Stars Confirmed for Games of the Future 2025 Some of the biggest names in phygital sports and esports from around the world will head to Abu Dhabi for the ultimate showdown in next-gen sports from 18-23 December. Phygital International, the UAE-based promoter of phygital sports globally, has just confirmed the lineup for the Games of the Future Abu Dhabi 2025 (GOTF...

Continue Reading
Rhythm Pharmaceuticals Earnings Report: What to Watch For

Updated Category News Views 239

Eyes on Rhythm Pharmaceuticals: Earnings Just Around the Corner A steady hum of anticipation is in the air as Rhythm Pharmaceuticals (NASDAQ:RYTM) gears up to unveil its quarterly earnings on February 26, 2026. While investors hung onto the last report’s fallout, expectations this time are swirling around whether RYTM can turn things around after a slip last quarter....

Continue Reading
First Capital REIT Reports Impressive Q3 2024 Growth Metrics

Updated Category News Views 239

First Capital REIT's Strong Q3 Results Highlight Robust Performance First Capital Real Estate Investment Trust (TSX: FCR) has announced remarkable financial results for the third quarter ending September 30, indicating robust operational performance backed by strong leasing activities. The detailed report is made accessible to investors on the Trust's official website....

Continue Reading
Sherwin-Williams Faces Challenges After Lowering Earnings Outlook

Updated Category News Views 168

Sherwin-Williams Adjusts Earnings Projections Following Q2 Results The Sherwin-Williams Company (NYSE: SHW) recently faced some challenges after reporting lower-than-expected second-quarter earnings. With adjusted earnings per share (EPS) of $3.38, the results fell short of Wall Street's predictions, which had estimated $3.81 per share. The company's quarterly revenue,...

Continue Reading
Oculis Financial Results & Clinical Update for Q2 2024

Updated Category News Views 108

Oculis Reports Q2 Financial Results and Company Update Oculis Holding AG (NASDAQ: OCS; XICE: OCS), a global biopharmaceutical company focused on improving eye care, has shared its latest financial results and significant developments. The highlights from the second quarter ending June 30, 2024, illustrate the company's dedication to advancing its innovative clinical...

Continue Reading